Pharmakon Advisors, LP the investment manager of the BioPharma Credit Investment funds has committed over $10 billion across 59 transactions supporting companies in the life sciences (including biotechnology, pharmaceuticals, medical technology and diagnostics).

Since its founding in 2009, Pharmakon has raised approximately $5.1 billion across five private funds and a publicly traded UK trust: BioPharma Credit PLC (ticker: BPCR.L), which was listed on the London Stock Exchange in March 2017.

Pharmakon’s investment approach is comprehensive and flexible, specializing in providing non-dilutive debt capital to a broad spectrum of life sciences companies – from emerging growth innovators to established commercial-stage companies. 

Our team is composed of seasoned professionals with deep expertise spanning biotechnology, pharmaceuticals, medical technology and finance. This collective experience enables Pharmakon to deliver customized financing solutions for companies while generating competitive risk-adjusted returns for investors.

At Pharmakon, we are committed to fostering innovation and growth within the life sciences industry and providing our borrowers with the capital, partnership and strategic support they need to bring healthcare advances to patients globally.